NYSE:AMAM Ambrx Biopharma (AMAM) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free AMAM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$28.00▼$28.0050-Day Range$27.70▼$28.0052-Week Range$6.55▼$28.15VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$23.29 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends Get Ambrx Biopharma alerts: Email Address Ambrx Biopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside16.8% Downside$23.29 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.45) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.06 out of 5 starsMedical Sector914th out of 916 stocksBiological Products, Except Diagnostic Industry154th out of 154 stocks 1.2 Analyst's Opinion Consensus RatingAmbrx Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmbrx Biopharma has received no research coverage in the past 90 days.Read more about Ambrx Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AMAM. Previous Next 0.0 Dividend Strength Dividend YieldAmbrx Biopharma does not currently pay a dividend.Dividend GrowthAmbrx Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMAM. Previous Next 0.6 News and Social Media Coverage Search Interest9 people have searched for AMAM on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Ambrx Biopharma is held by insiders.Percentage Held by Institutions77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ambrx Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.45) to ($1.28) per share.Price to Book Value per Share RatioAmbrx Biopharma has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Ambrx Biopharma Stock (NYSE:AMAM)Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Read More Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution AMAM Stock News HeadlinesMay 24, 2024 | finance.yahoo.com14 Day AMERIBOR Average Rate (^AMBRX)April 5, 2024 | benzinga.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)June 27, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…March 7, 2024 | finanznachrichten.deAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | markets.businessinsider.comJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 6, 2024 | globenewswire.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonFebruary 23, 2024 | investorplace.com3 Stocks to Buy That Are Up 200% or More in 2024February 20, 2024 | msn.comIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?June 27, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…February 12, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMFebruary 10, 2024 | businesswire.comAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPJanuary 11, 2024 | msn.comJMP Securities Downgrades Ambrx Biopharma (AMAM)January 10, 2024 | realmoney.thestreet.comAmbrx Biopharma just downgraded at JMP Securities, here's whyJanuary 9, 2024 | finance.yahoo.comAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&JJanuary 8, 2024 | nasdaq.comJ&J to buy cancer therapy developer Ambrx for $2 blnJanuary 8, 2024 | tmcnet.comAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersJanuary 8, 2024 | markets.businessinsider.comCrude Oil Falls Sharply; Ambrx Biopharma Shares Spike HigherJanuary 8, 2024 | investorplace.comWhy Is Ambrx Biopharma (AMAM) Stock Up 100% Today?January 8, 2024 | reuters.comJohnson & Johnson to buy Ambrx Biopharma for $2 blnJanuary 8, 2024 | finance.yahoo.comAmbrx Announces Sale to Johnson & JohnsonDecember 14, 2023 | msn.comAmbrix to Join NASDAQ Biotech IndexDecember 14, 2023 | finance.yahoo.comAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)November 29, 2023 | markets.businessinsider.comOptimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy RatingNovember 28, 2023 | finance.yahoo.comAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerNovember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)November 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)See More Headlines Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AMAM CUSIPN/A CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$23.29 High Stock Price Target$32.00 Low Stock Price Target$9.00 Potential Upside/Downside-16.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$7.40 million Price / Sales238.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book9.18Miscellaneous Outstanding Shares63,150,000Free Float62,746,000Market Cap$1.77 billion OptionableOptionable Beta-1.92 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Daniel J. O'Connor J.D. (Age 59)CEO, President & Director Comp: $509.94kMs. Sonja Nelson CPA (Age 51)Chief Financial Officer Comp: $1.18MMr. Andrew P. Aromando (Age 55)Chief Operating Officer Dr. Ying J. Buechler Ph.D.Chief Technology OfficerDr. Shawn Shao-Hui Zhang Ph.D.Chief Scientific Officer & GM of ChinaMr. Jared KellySenior VP, General Counsel & Corporate SecretaryMr. Robert AzzaraVice President of Human CapitalDr. Sandra Aung Ph.D.Chief Clinical OfficerMs. Renu Vaish M.Sc. (Age 57)Chief Regulatory Officer More ExecutivesKey CompetitorsRepligenNASDAQ:RGENExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALORevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSView All CompetitorsInsidersDaniel J O'connorSold 50,012 sharesTotal: $491,117.84 ($9.82/share)Sonja NelsonSold 12,778 sharesTotal: $125,479.96 ($9.82/share)Cormorant Asset Management, LpBought 1,307,311 shares on 10/23/2023Total: $9.14 M ($6.99/share)Cormorant Asset Management, LpBought 751,233 shares on 9/18/2023Total: $6.94 M ($9.24/share)Cormorant Asset Management, LpBought 1,401,505 shares on 9/15/2023Total: $12.68 M ($9.05/share)View All Insider Transactions AMAM Stock Analysis - Frequently Asked Questions Should I buy or sell Ambrx Biopharma stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMAM, but not buy additional shares or sell existing shares. View AMAM analyst ratings or view top-rated stocks. What is Ambrx Biopharma's stock price target for 2024? 7 Wall Street research analysts have issued 12-month price targets for Ambrx Biopharma's stock. Their AMAM share price targets range from $9.00 to $32.00. On average, they expect the company's stock price to reach $23.29 in the next year. This suggests that the stock has a possible downside of 16.8%. View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts. What ETF holds Ambrx Biopharma's stock? AltShares Merger Arbitrage ETF holds 42,594 shares of AMAM stock, representing 1.95% of its portfolio. When did Ambrx Biopharma IPO? Ambrx Biopharma (AMAM) raised $126 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO. This page (NYSE:AMAM) was last updated on 6/27/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambrx Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.